Zealand Pharma A/s Stock
Zealand Pharma A/s Stock
The price for the Zealand Pharma A/s stock decreased slightly today. Compared to yesterday there is a change of -€0.070 (-0.160%).
So far the community has only identified positive things for Zealand Pharma A/s stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Zealand Pharma A/s in the next few years
Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Zealand Pharma A/s vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Zealand Pharma A/s | -0.160% | 7.066% | 10.025% | 4.436% | -31.557% | 50.378% | 70.257% |
| Saniona AB | -2.030% | -2.273% | 2.381% | 55.355% | -37.226% | 57.386% | -33.111% |
| Ocuphire Pharma Inc. | - | 18.382% | -9.551% | 246.609% | 91.439% | -14.589% | -13.441% |
| NanoViricides Inc. | -3.100% | -5.303% | 9.649% | -6.716% | 34.409% | 0.000% | -61.586% |
News
Beauty Health Q2 Earnings Call Highlights
Key Points
- Interested in The Beauty Health Company? Here are five stocks we like better.
- Second-quarter results were mixed: Revenue fell 7.8% year over year to $72.1 million, pressured by
Vir Biotechnology Q2 Earnings Call Highlights
Vir Biotechnology (NASDAQ:VIR) reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs
Remitly Global Q2 Earnings Call Highlights
Key Points
- Interested in Remitly Global, Inc.? Here are five stocks we like better.
- Strong second-quarter performance: Revenue rose 20% year over year to $495 million, while adjusted EBITDA